Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer

▴ Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer
Only HER2-directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that offer significant advances over available options by demonstrating safety or efficacy improvements, preventing serious conditions, or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, will be during the first quarter of 2021.

There are more than 27,000 new cases of gastric cancer in the US each year, of which approximately one in five are HER2 positive. For patients with metastatic gastric cancer who progress on initial treatment with an anti-HER2 medicine, there are no other approved HER2-directed medicines.

José Baselga, Executive Vice President, Oncology R&D, said: “Once patients with HER2-positive metastatic gastric cancer progress following initial treatment with an anti-HER2 regimen, there are no approved HER2-directed medicines. The prognosis for these patients is poor, as available treatment options offer only limited clinical benefit. This milestone brings us one step closer to delivering a potentially practice-changing medicine to patients with gastric cancer in the US.”

Antoine Yver, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo, said: “The results of the DESTINY-Gastric01 trial are unprecedented as they represent the first time a HER2-directed medicine has demonstrated an improvement in survival following chemotherapy and HER2 treatment in the metastatic setting. Building on the recent Breakthrough Therapy Designation, the filing of the application and Priority Review by the FDA for this potential new indication for Enhertu reflects the importance of the data and the significant unmet need for patients with previously treated HER2-positive metastatic gastric cancer.”

Tags : #LatestPhramaNewsOct28 #LatestAstrazenecaNewsOct28 #treatmentforgastriccancer #treamentforcancer

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Gestational diabetes - Will it affect my baby? November 30, 2020
PM to interact with 3 teams involved in developing COVID-19 vaccine.November 30, 2020
Uttarakhand govt makes Covid-19 test mandatory for entry November 30, 2020
Unichem gets US FDA approval for Atenolol and Chlorthalidone TabletsNovember 30, 2020
Dr Reddy’s buys select anti-allergy brands from Glenmark in Russia and other CIS countries November 30, 2020
Government Launches Mission COVID Suraksha to accelerate Indian COVID-19 Vaccine Development November 30, 2020
71% of the daily fatalities contributed by eight States/UT - Delhi, Maharashtra, WB, Haryana, Punjab, Kerala, Uttar Pradesh and RajasthanNovember 30, 2020
Rajasthan govt decides to close schools, colleges, cinema, entertainment parks in state till Dec 31 November 30, 2020
India Covid-19 News Updates :Nov 29, 2020November 29, 2020
PM congratulates scientists on progress of Covid19 vaccine at Bharat BiotechNovember 28, 2020
COVID-19 recovery rate in country stands at 93.68 percent.November 28, 2020
Vertex Pharma received European Commission Approval for SYMKEVI With KALYDECONovember 28, 2020
Co-Diagnostics JV CoSara Diagnostics receives clearance from CDSCO for COVID-19 2-Gene Multiplex TestNovember 28, 2020
SAL unveils new pharma and perishable facilities in Riyadh in time for COVID vaccines distributionNovember 28, 2020
Number of Covid tests per million population in country cross one lakh markNovember 28, 2020
How can I lower cholesterol with diet?November 28, 2020
Breakthrough in AML Treatment: GoldenBiotech reports new drug trial of Antroquinonol November 28, 2020
Gujarat records 1607 new cases of COVID-19November 28, 2020
Number of active cases of COVID-19 drop down to 120 in Andaman & Nicobar IslandsNovember 28, 2020
Number of covid-19 recoveries reach 3,09,747 in OdishaNovember 28, 2020